Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma.
Parker JM, Oh CK, LaForce C, Miller SD, Pearlman DS, Le C, Robbie GJ, White WI, White B, Molfino NA; MEDI-528 Clinical Trials Group. Parker JM, et al. Among authors: le c. BMC Pulm Med. 2011 Feb 28;11:14. doi: 10.1186/1471-2466-11-14. BMC Pulm Med. 2011. PMID: 21356110 Free PMC article. Clinical Trial.
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, Robbie G, Levin R, Berney SM, Chindalore V, Olsen N, Richman L, Le C, Jallal B, White B; Lupus Interferon Skin Activity (LISA) Study Investigators. Merrill JT, et al. Among authors: le c. Ann Rheum Dis. 2011 Nov;70(11):1905-13. doi: 10.1136/ard.2010.144485. Epub 2011 Jul 27. Ann Rheum Dis. 2011. PMID: 21798883 Clinical Trial.
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients.
Higgs BW, Zhu W, Morehouse C, White WI, Brohawn P, Guo X, Rebelatto M, Le C, Amato A, Fiorentino D, Greenberg SA, Drappa J, Richman L, Greth W, Jallal B, Yao Y. Higgs BW, et al. Among authors: le c. Ann Rheum Dis. 2014 Jan;73(1):256-62. doi: 10.1136/annrheumdis-2012-202794. Epub 2013 Feb 23. Ann Rheum Dis. 2014. PMID: 23434567 Free PMC article. Clinical Trial.
Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial.
Kokai-Kun JF, Roberts T, Coughlin O, Le C, Whalen H, Stevenson R, Wacher VJ, Sliman J. Kokai-Kun JF, et al. Among authors: le c. Lancet Infect Dis. 2019 May;19(5):487-496. doi: 10.1016/S1473-3099(18)30731-X. Epub 2019 Mar 15. Lancet Infect Dis. 2019. PMID: 30885591 Clinical Trial.
Selection of a cut-off for high- and low-methane producers using a spot-methane breath test: results from a large north American dataset of hydrogen, methane and carbon dioxide measurements in breath.
Gottlieb K, Le C, Wacher V, Sliman J, Cruz C, Porter T, Carter S. Gottlieb K, et al. Among authors: le c. Gastroenterol Rep (Oxf). 2017 Aug;5(3):193-199. doi: 10.1093/gastro/gow048. Epub 2017 Jan 27. Gastroenterol Rep (Oxf). 2017. PMID: 28130375 Free PMC article.
Erratum: Selection of a cut-off for high- and low-methane producers using a spot-methane breath test: results from a large north American dataset of hydrogen, methane and carbon dioxide measurements in breath.
Gottlieb K, Le C, Wacher V, Sliman J, Cruz C, Porter T, Carter S. Gottlieb K, et al. Among authors: le c. Gastroenterol Rep (Oxf). 2018 Aug;6(3):242. doi: 10.1093/gastro/gox015. Epub 2017 Apr 27. Gastroenterol Rep (Oxf). 2018. PMID: 30151210 Free PMC article.
Outcomes of Immunotherapy Treatment in Sinonasal Mucosal Melanoma.
Kshirsagar RS, Eide JG, Harris J, Abiri A, Beswick DM, Chang EH, Fung N, Hong M, Johnson BJ, Kohanski MA, Le CH, Lee JT, Nabavizadeh SA, Obermeyer IP, Pandrangi VC, Pinheiro-Neto CD, Smith TL, Snyderman CH, Suh JD, Wang EW, Wang MB, Choby G, Geltzeiler M, Lazor J, Mitchell TC, Kuan EC, Palmer JN, Adappa ND. Kshirsagar RS, et al. Among authors: le ch. Am J Rhinol Allergy. 2025 Jan 9:19458924241308953. doi: 10.1177/19458924241308953. Online ahead of print. Am J Rhinol Allergy. 2025. PMID: 39782303
1,109 results